Brief: SK Bioscience And CEPI Sign Agreement To Develop Mrna Vaccines
25/10/2022 13:37
Oct 25 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* SK BIOSCIENCE AND CEPI SIGN AGREEMENT TO DEVELOP MRNA
VACCINES
* SK BIOSCIENCE CO LTD - CEPI SUPPORTS UP TO $40 MILLION FOR
EARLY
DEVELOPMENT OF MRNA VACCINE PLATFORM TO CO
* SK BIOSCIENCE CO LTD - UP TO $40 MILLION IN INITIAL
FUNDING WILL
BE AVAILABLE TO SUPPORT PHASE 1/2 CLINICAL TRIALS OF TWO MRNA
VACCINE PLATFORM PROJECT
Source text for Eikon: ID:nPn2VZgh6a
Further company coverage: 302440.KS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine